CDKI-83

• Description:

  CDKI-83 is a potent CDK9 and CDK1 inhibitor with Ki values of 21 nM and 72 nM for CDK9/T1 and CDK1/B, respectively. CDKI-83 demonstrates effective anti-proliferative activity in human tumour cell lines with a GI50apoptosis in A2780 human ovarian cancer cells. CDKI-83 reduces phosphorylation at Ser-2 of RNA polymerase II (RNAPII) by inhibiting cellular CDK9 activity, and down-regulates Mcl-1 and Bcl-2. CDKI-83 has the potential for anti-cancer research[1].

• UNSPSC:

  12352005

• Target:

  Apoptosis; Bcl-2 Family; CDK

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cdki-83.html

• Smiles:

  N#CC1=CN=C(N=C1C2=C(N=C(S2)NC)C)NC3=CC=C(C(S(=O)(N4CCOCC4)=O)=C3)C

• Molecular Formula:

  C21H23N7O3S2

• Molecular Weight:

  485.58

• References & Citations:

  [1]Xiangrui Liu, et al. In vitro antitumor mechanism of a novel cyclin-dependent kinase inhibitor CDKI-83. Invest New Drugs. 2012 Jun;30 (3) :889-97.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  CDK1; CDK2; CDK4; CDK7; CDK9

• CAS Number:

  1189558-88-0